Ocugen, Inc. Common Stock (OCGN) is a publicly traded Healthcare sector company. As of May 21, 2026, OCGN trades at $1.36 with a market cap of $453.62M and a P/E ratio of 0.00. OCGN moved +5.38% today. Year to date, OCGN is -6.21%; over the trailing twelve months it is +67.90%. Its 52-week range spans $0.52 to $2.73. Analyst consensus is strong buy with an average price target of $11.57. Rallies surfaces OCGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ocugen closes $130M 6.75% convertible notes sale, extends runway to 2028: Ocugen raised $130 million via 6.75% convertible senior notes due 2034, including $15 million overallotment, yielding $112.6 million net proceeds. It allocated $32.7 million to repay its Avenue Capital loan and will use the balance for corporate purposes, extending its cash runway into 2028 to advance three late-stage gene therapy programs toward BLA filings.
| Metric | Value |
|---|---|
| Price | $1.36 |
| Market Cap | $453.62M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.73 |
| 52-Week Low | $0.52 |
| Volume | 7.12K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.41M |
| Net Income | $-67.85M |
| Gross Margin | 0.00% |
7 analysts cover OCGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.57.